LOS ANGELES--(BUSINESS WIRE)--An emerging company developing biotechnology invented at UCLA is adapting their approach to address the novel coronavirus, with the goal of adding to the anti-COVID-19 arsenal that follows an initial vaccine. The company, Vault Pharma, is working with UCLA and other universities to advance a vaccine with the potential to treat the virus in addition to protecting against it. Vault Pharma was co-founded by Leonard H. Rome, distinguished professor of biological chemistry and...
Read More
ARDS has been identified as the leading cause of COVID-19-related fatalities; in preclinical studies, Orbsen Therapeutics’ proprietary ORBCEL cellular therapy demonstrated the ability to mitigate the effects of ARDS by improving lung oxygenation, lessening inflammation, reducing edema and decreasing bacterial infection LOS ANGELES, April 15, 2020 (GLOBE NEWSWIRE) — via NetworkWire – Addressing the finding that most fatalities from COVID-19 are caused by the nonreversible development of acute respiratory distress syndrome (ARDS), Multiverse Investment Fund I, LP, a private…
Finalists in Global Competition to Present to Members of Investment and Venture Capitalists Communities Los Angeles, CA: (PRWEB) June 15, 2017 — Vault Pharma, an immunology-focused biotechnology company developing precision therapies for cancer, Women’s health, and infectious diseases, has been selected as a finalist and will present before an international panel of judges and investors on June 21, 2017, in San Diego at Start-Up Stadium at the BIO International Convention, the world’s largest biotechnology event….
Two new board members have histories of building successful pharma companies. Los Angeles, CA (PRWEB) May 08, 2017 — Vault Pharma, an immunology-focused biotechnology company developing precision therapies for cancer and infectious diseases, named Michael J. Kamdar, Chief Executive Officer and Director at Molecular Assemblies Inc., and Todd N. Smith, Chief Executive Officer at Novum Pharma, to the company’s Board of Directors. “Mike and Todd add depth, experience and leadership to an already distinguished group…
Experienced Biotech Leader To Guide Company As Therapies Enter Clinical Trials (PRWEB) April 27, 2017 — Los Angeles – Vault Pharma, an immunology-focused biotechnology company developing precision therapies for cancer and infectious diseases, named Oliver Foellmer as President and Chief Executive Officer. Vault Pharma is developing a unique therapeutics platform using the body’s own naturally occurring vault protein particles found abundantly in human cells to activate the immune system against cancer cells, bacteria and viruses….
